Eli Lilly and Company (NYSE: LLY) reported positive results from a phase 3 trial of orforglipron, an investigational oral GLP-1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE